/
INMD
$14.59-$0.04 (-0.31%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$840.9M
57M shares
52-week range
$12.72 – $16.74
46% from low
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-32.76
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $100.2M | $156.4M | $206.1M | $357.6M | $454.3M | $492.0M | $394.8M | $370.5M |
| Cost of revenue | $15.1M | $20.2M | $30.8M | $53.6M | $73.5M | $80.7M | $77.8M | $79.5M |
| Gross profit | $85.1M | $136.1M | $175.3M | $304.0M | $380.8M | $411.3M | $317.1M | $291.0M |
| Gross margin | 85.0% | 87.1% | 85.0% | 85.0% | 83.8% | 83.6% | 80.3% | 78.5% |
| R&D | $4.2M | $5.7M | $9.5M | $9.5M | $12.4M | $13.4M | $13.1M | $13.3M |
| Operating income | $23.5M | $59.6M | $72.8M | $167.5M | $197.9M | $195.7M | $112.5M | $85.4M |
| EBITDA | $31.7M | $59.9M | $73.3M | $168.5M | $202.1M | $217.9M | $144.2M | $111.0M |
| Net income | $22.4M | $61.1M | $75.0M | $165.0M | $161.5M | $197.9M | $181.3M | $93.8M |
| Net margin | 22.3% | 39.1% | 36.4% | 46.1% | 35.6% | 40.2% | 45.9% | 25.3% |
| EPS (diluted) | 0.35 | 0.80 | 0.89 | 1.92 | 1.89 | 2.30 | 2.25 | 1.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $370M | $1.34 | $1.32–$1.35 | 3 |
| 2027 | $378M | $1.45 | $1.37–$1.56 | 5 |
| 2028 | $389M | $1.51 | $1.33–$1.74 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$36.35
Price
$14.59
Implied upside
+149%
Peer comparison
InMode Ltd. Ordinary Shares
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
www.inmodemd.com- Employees
- 660
- IPO / List date
- Aug 8, 2019
Held by traders on TradeandTell
No one on the platform currently holds INMD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in INMD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2021-10-01 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded INMD yet.
